Peer-led Trauma Therapy for Re-entry
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06019767 |
Recruitment Status :
Recruiting
First Posted : August 31, 2023
Last Update Posted : May 8, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of the research is to learn more about how to treat PTSD for people directly impacted by incarceration (i.e., have spent time in prison or jail). This research will help identify if a PTSD treatment group that is used in community settings, and led by individuals with lived experience, is helpful in reducing PTSD symptoms among people who have been directly impacted by incarceration.
Participants will complete an interview to determine whether they are experiencing PTSD, and if so, will participate in a 6-week therapy group treatment.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
PTSD | Behavioral: Cognitive Processing Therapy | Not Applicable |
Two community Certified Peer Specialists (CPSs) who have experienced incarceration and re-entry from prison, and who have experienced trauma will be trained on delivering group Cognitive Processing Therapy (CPT).
Working with the Wisconsin Department of Health Services (DHS) and community organizations serving formerly incarcerated individuals, researchers will screen individuals for PTSD treatment need, and invite 24 eligible individuals to participate in group CPT co-led by one of the trained CPSs and a trained community therapist or provider.
Eligible participants who are enrolled in the study will be invited to complete a 6-week (12 sessions total) group CPT therapy treatment for PTSD. Participants will also complete pre-, mid-, and post-treatment mental health surveys. Participants will also complete a post-treatment focus group where they are asked about their experience in the therapy and to provide feedback on the study as a whole.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 72 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Peer-led Trauma Therapy for Re-entry |
Actual Study Start Date : | November 14, 2023 |
Estimated Primary Completion Date : | September 2025 |
Estimated Study Completion Date : | September 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Cognitive Processing Therapy (CPT)
Groups of 6-8 receive CPT to treat PTSD
|
Behavioral: Cognitive Processing Therapy
CPT is a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups. |
- Feasibility: Participation [ Time Frame: Study duration (up to 2 years) ]Will be measured as the percentage of invited, eligible individuals who elect to participate.
- Feasibility: Rate of retention [ Time Frame: Study duration (up to 2 years) ]Will be measured by percentage of participants who complete at least 9 of the 12 study sessions
- Feasibility: Compliance through participation [ Time Frame: Study duration (up to 2 years) ]Will be measured by percentage of participants performing intervention activities during session, such as contributing to the discussion.
- Feasibility: Compliance through homework [ Time Frame: Study duration (up to 2 years) ]Will be measured by percentage of participants completing homework assignments each week.
- Feasibility: Compliance through completing assessments [ Time Frame: Study duration (up to 2 years) ]Will be measured by percentage of participants completing the pre-, mid-, and post-intervention assessment batteries.
- Ratings from 0-5 by clinical supervisors on therapist adherence to five session elements [ Time Frame: Study duration (up to 2 years) ]Higher ratings indicate better adherence to session elements. Assesses for therapist adherence to CPT guidelines as secondary measure of intervention efficacy.
- Ratings 1-7 by clinical supervisors on quality of session elements delivered by therapist [ Time Frame: Study duration (up to 2 years) ]Higher ratings indicate higher-quality session element (scores 1-7; 1=not satisfactory, 4= satisfactory, 7=excellent) by the clinical supervisor. Assesses for therapist compliance as secondary measure of intervention efficacy.
- Change in suicide and self-harm ideation [ Time Frame: Baseline to end of follow-up (up to 4.5 months) ]Beck Depression Inventory-II (BDI-II), item 9. Participants will answer the item on a scale of 0-3, where a score of 2 or 3 indicates higher ideation.
- Participant satisfaction [ Time Frame: One week post-treatment (up to 7 weeks) ]Using the 8 item Client Satisfaction Questionnaire (CSQ-8), participants will rate their satisfaction with their experience. Scale ranges from 1-4, with total potential scores of 8 to 32 with higher scores indicating greater satisfaction.
- Change in PTSD symptom severity [ Time Frame: Baseline to end of follow-up (up to 4.5 months) ]Using the PTSD Checklist for DSM-5 (PCL-5), which is a 20-item self-report measure, symptoms of PTSD will be assessed. Participants will answer items on a scale of 0-4, where 0=Not at all and 4=Extremely. Higher scores indicate higher symptom severity.
- Change in depression symptom severity [ Time Frame: Baseline to end of follow-up (up to 4.5 months) ]Beck Depression Inventory-II (BDI-II), which is a 21-item self-report measure to assess depression severity. Participants will answer items on a scale of 0-3, where lower scores indicate lower severity.
- Change in trauma related thoughts and beliefs [ Time Frame: Baseline to end of follow-up (up to 4.5 months) ]Posttraumatic Cognitions Inventory (PTCI) is a 33-item measure of negative cognition about the world, negative self-related thoughts, and self-blame. Participants rate each item on a scale of 1-7, 1=totally disagree, 4=neutral, 7=totally agree. Higher scores indicate greater levels of trauma.
- Change in aspects of hopelessness [ Time Frame: Baseline to end of follow-up (up to 4.5 months) ]Beck Hopelessness Scale is a 20-item questionnaire, which participants answer true or false.
- Change in substance use [ Time Frame: Baseline to end of follow-up (up to 4.5 months) ]Tobacco, Alcohol, Prescription Medication, and other Substance Use Tool (TAPS) screens for tobacco use, alcohol use, prescription medication misuse, and illicit substance use in the past year, as well as the past 3 months.
- Change in anxiety symptom severity [ Time Frame: Baseline to end of follow-up (up to 4.5 months) ]Beck Anxiety Inventory (BAI), which is a 21-item self-report measure to assess anxiety severity. Participants will rate how much items bothered them as: Not at all; Mildly but it didn't bother me much; Moderately - it wasn't pleasant at times; or, Severely - it bothered me a lot. More symptoms that caused moderate or severe bother indicate higher severity of anxiety.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 years of age or older
- completed a prison or jail sentence
- no current psychosis symptoms
- no active self-harm or active suicidal intent
- able and willing to participate in group therapy
- meet criteria for PTSD treatment need
Exclusion Criteria:
- current and active psychosis
- current and active self-harm and suicidality
- no PTSD diagnosis
- current substance use dependence (not including those used as prescribed for medical reasons) on cocaine, amphetamines, inhalants, sedatives or sleeping pills, hallucinogens, or opioids
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06019767
Contact: Michael Koenigs, PhD | 608-263-1679 | mrkoenigs@wisc.edu |
United States, Wisconsin | |
University of Wisconsin | Recruiting |
Madison, Wisconsin, United States, 53705 | |
Contact: Michael Koenigs, PhD 608-263-1679 mrkoenigs@wisc.edu | |
Principal Investigator: Michael Koenigs, PhD |
Principal Investigator: | Michael Koenigs, PhD | University of Wisconsin, Madison |
Responsible Party: | University of Wisconsin, Madison |
ClinicalTrials.gov Identifier: | NCT06019767 |
Other Study ID Numbers: |
2023-1144 Protocol Version 8/11/23 ( Other Identifier: UW Madison ) SMPH/PSYCHIATRY/PSYCHIATRY ( Other Identifier: UW Madison ) |
First Posted: | August 31, 2023 Key Record Dates |
Last Update Posted: | May 8, 2024 |
Last Verified: | May 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Previously incarcerated Group therapy Cognitive Processing Therapy |